CymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading Volume
Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) saw strong trading volume on Wednesday . 4,816,100 shares were traded during trading, an increase of 295% from the previous session’s volume of 1,220,599 shares.The stock last traded at $1.56 and had previously closed at $1.55.
Several analysts have recently commented on the company. Raymond James cut CymaBay Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Tuesday, November 26th. Cantor Fitzgerald cut CymaBay Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $20.00 to $2.00 in a report on Tuesday, November 26th. SunTrust Banks cut CymaBay Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 25th. Oppenheimer cut CymaBay Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, November 25th. Finally, Svb Leerink restated a “market perform” rating on shares of CymaBay Therapeutics in a report on Thursday, January 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $6.56.
The company has a debt-to-equity ratio of 0.01, a current ratio of 13.12 and a quick ratio of 13.12. The firm has a market cap of $107.17 million, a price-to-earnings ratio of -1.15 and a beta of 1.20. The firm has a 50 day moving average price of $1.81 and a 200-day moving average price of $3.96.
About CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Recommended Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.